NCT04802876: Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
- State
- Under way
- Phase
- Phase 2
- People
- 184 planned
- Started
- 12 Apr 2021
- Primary completion
- 30 Sep 2025
- Arms
- Spartalizumab (PDR001) (Cohort-1 PD1-high), Spartalizumab (PDR001) (Cohort-2 PD1-low)
- Results
- None posted
- 17 Mar 2021: Trial registered
- 12 Apr 2021: Trial started